Data standards for minimum information collection for antibody therapy experiments

Yong, May; Tolner, Berend; Nagl, Scb; Pedley, RB; Chester, KA; Green, A.J.; Mayer, Allen; Sharma, Sunil; Begent, R. H. J.

doi:10.1093/protein/gzp003

Cited by 6 publications

(2 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Guidelines and Information about Therapy Experiments (GIATE) is a reporting guideline for recording diverse information on therapy experiments [32]. Where possible, GIATE provides links to public data repositories, so that information kept in those databases may be linked to GIATE data.…”

Section: Guidelines and Information About Therapy Experiments For Buildmentioning

confidence: 99%

Best Use of Experimental Data in Cancer Informatics

Yong

Begent²

2010

Future Oncol.

View full text Add to dashboard Cite

The welcome attitude of the 'omics community, journals and funders of research towards data sharing, coupled with successful implementations of data standards, has resulted in resource dissemination and a better understanding of many diseases, including cancer. Sharing experiment data is beneficial in terms of knowledge generation, allowing reproduction and validation of results. An adherence to a reporting guideline enables full-value extraction from costly data; this is an inexpensive method to increased quality without incurring disproportionate costs. For therapy data in particular, easy access to the range of new approaches and the ability to perform valid comparisons between these approaches would be especially useful. We discuss initiatives that support resource sharing and summarize three reporting guidelines for experiment data that have been adopted successfully. Finally, we introduce a new guideline that encompasses the diverse data types in therapeutic experiments, which is intended to be of use to the cancer therapeutics community.

show abstract

Section: Guidelines and Information About Therapy Experiments For Buildmentioning

confidence: 99%

Best Use of Experimental Data in Cancer Informatics

Yong

Begent²

2010

Future Oncol.

View full text Add to dashboard Cite

show abstract

“…GIATE originated from a collaboration among members of the Antibody Society [22], who worked at identifying the main elements that should be recorded for antibody therapy experiments [23]. Initially, GIATE was represented as a set of Common Data Elements (CDEs), as per the ISO/IEC 11179 metadata registries' standard [24].…”

Section: Introductionmentioning

confidence: 99%

Guidelines for information about therapy experiments: a proposal on best practice for recording experimental data on cancer therapy

et al. 2012

View full text Add to dashboard Cite

BackgroundBiology, biomedicine and healthcare have become data-driven enterprises, where scientists and clinicians need to generate, access, validate, interpret and integrate different kinds of experimental and patient-related data. Thus, recording and reporting of data in a systematic and unambiguous fashion is crucial to allow aggregation and re-use of data. This paper reviews the benefits of existing biomedical data standards and focuses on key elements to record experiments for therapy development. Specifically, we describe the experiments performed in molecular, cellular, animal and clinical models. We also provide an example set of elements for a therapy tested in a phase I clinical trial.FindingsWe introduce the Guidelines for Information About Therapy Experiments (GIATE), a minimum information checklist creating a consistent framework to transparently report the purpose, methods and results of the therapeutic experiments. A discussion on the scope, design and structure of the guidelines is presented, together with a description of the intended audience. We also present complementary resources such as a classification scheme, and two alternative ways of creating GIATE information: an electronic lab notebook and a simple spreadsheet-based format. Finally, we use GIATE to record the details of the phase I clinical trial of CHT-25 for patients with refractory lymphomas. The benefits of using GIATE for this experiment are discussed.ConclusionsWhile data standards are being developed to facilitate data sharing and integration in various aspects of experimental medicine, such as genomics and clinical data, no previous work focused on therapy development. We propose a checklist for therapy experiments and demonstrate its use in the 131Iodine labeled CHT-25 chimeric antibody cancer therapy. As future work, we will expand the set of GIATE tools to continue to encourage its use by cancer researchers, and we will engineer an ontology to annotate GIATE elements and facilitate unambiguous interpretation and data integration.

show abstract